Bayer strengthens its pipeline story, shares in DAX trade

By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-23, 11:31.

Bayer (DE000BAY0017) pairs a clinical update from its Vividion unit with Tuesday trade on Xetra. The company said on 23 June that Vividion Therapeutics treated the first patient in a Phase Ib combination study with VVD-214, a WRN inhibitor for advanced colorectal cancer. Bayer newsroom release

What Bayer disclosed

Bayer said the global Phase Ib study evaluates VVD-214 in patients with previously treated MSI-H or dMMR colorectal cancer. The research focus sits inside Bayer's wider oncology pipeline and gives the group another dated clinical milestone for the market to track.

Tuesday market angle

Frankfurt keeps Bayer in a clear local frame, and the stock remains a DAX component. On Tuesday, the most relevant lens is consensus and the recent chart setup, with the shares trading around 37.75 euros on finanzen.net at 11:31 UTC. finanzen.net chart for Bayer

The product behind Bayer

One representative product line is Asundexian, Bayer's anticoagulation candidate in development. The company also highlighted VVD-214, which sits in its oncology research effort through Vividion Therapeutics.

Bayer shares at midday

The Bayer shares (DE000BAY0017) trade on 2026-06-23, 11:31 UTC at 37.75 euros on Frankfurt-linked trading screens. The same timestamp and price are used in the fact box below.

Disclaimer: This article is for information only and does not constitute investment advice.